Searchable abstracts of presentations at key conferences in endocrinology

ea0037oc5.5 | Steroids, developmental and paediatric endocrinology | ECE2015

Pituitary hormone secretion profiles in IGSF1 deficiency syndrome

Joustra Sjoerd , Roelfsema Ferdinand , Endert Erik , Ballieux Bart , van Trotsenburg Paul , Fliers Eric , Corssmit Noortje , Bernard Daniel , Oostdijk Wilma , Wit Jan-Maarten , Pereira Alberto , Biermasz Nienke

Context: Loss-of-function of immunoglobulin superfamily 1 (IGSF1) causes an X-linked syndrome of central hypothyroidism, macroorchidism, and variable prolactin deficiency, GH deficiency in childhood, delayed pubertal testosterone rise, and/or obesity. The clinical features advert towards a pivotal role for IGSF1 in the pituitary gland, but detailed knowledge on pituitary hormone secretion in this syndrome is lacking.Objective: To study detailed ...

ea0070oc4.6 | Pituitary and Neuroendocrinology | ECE2020

Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly

Samson Susan , Nachtigall Lisa , Fleseriu Maria , Gordon Murray , Ludlam William , Patou Gary , Haviv Asi , Molitch Mark E , Biermasz Nienke , Strasburger Christian J , Kennedy Laurence , Melmed Shlomo

Background: Many patients with acromegaly report limitations of long-acting somatostatin receptor ligand (SRL) injections, including ongoing disease symptoms near cycle-end and injection-site pain. Oral octreotide capsules (OOC) may provide an alternative to monthly injections. The phase 3 CHIASMA OPTIMAL study assessed efficacy and safety of OOC in patients with acromegaly controlled on injectable SRLs.Methods: A multinational, randomized, placebo-contr...

ea0070aep577 | Pituitary and Neuroendocrinology | ECE2020

Biochemical control of most patients reverting to injectable long-acting somatostatin receptor ligands is achieved after one dose: Results from the phase 3, randomized, double blind, placebo-controlled optimal study

Fleseriu Maria , Samson Susan , Nachtigall Lisa , Labadzhyan Artak , Elenkova Atanaska , Molitch Mark E , Ludlam William , Patou Gary , Haviv Asi , Biermasz Nienke , Strasburger Christian J , Kennedy Laurence , Melmed Shlomo

Background: Injectable somatostatin receptor ligands (SRLs) are currently the most widely used therapy for acromegaly. Oral octreotide capsules (OOC) are a potential therapy for acromegaly; the safety and efficacy were evaluated in the CHIASMA OPTIMAL pivotal study (Samson et al. ENDO 2020). As reported, mean IGF-I levels of the OOC group were maintained within normal range at end of treatment in all patients. However, some patients may not respond to OOC treatment (2...

ea0070aep595 | Pituitary and Neuroendocrinology | ECE2020

Gallium-68 -DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas

M. Boertien Tessel , Booij Jan , Majoie Charles BLM , Drent ML , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Groote Veldman Ronald , Stokkel Marcel PM , Bisschop Peter H , Fliers Eric

Background: Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express various somatostatin receptor (SSTR) subtypes, but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and 111In-DTPA-octreotide scintigraphy (Octreoscan) in vivo. The aim of this study was to assess SSTR expression in NFMA <em...

ea0070aep753 | Pituitary and Neuroendocrinology | ECE2020

SF-12 or SF-36 in pituitary disease? towards concise patient-reported outcomes measurements

Van der Meulen Merel , Biermasz Nienke , Zamanipoor Najafabadi Amir , Lobatto Daniel , van Furth Wouter , Andela Cornelie , Pereira Alberto M , Vliet-Vlieland Thea P.M.

Objective: Pituitary diseases cause a wide range of local and systemic symptoms and severely affect patients’ health-related quality of life (HRQoL), which can be monitored using both disease-specific and generic questionnaires. The most frequently used generic HRQoL questionnaire is the Short Form-36 (SF-36), generating a mental (MCS) and physical component score (PCS). The shorter 12-item version (SF-12) can improve efficiency of patient monitoring and outcome measurem...

ea0070aep1076 | Hot topics (including COVID-19) | ECE2020

Outcome squares integrating efficacy and safety, as applied to functioning pituitary adenoma surgery

de Vries Friso , Lobatto Daniel , Verstegen Marco , Schutte Pieter , Notting Irene , Kruit Mark , Ahmed Fasial , Pereira Alberto M , van Furth Wouter , Biermasz Nienke

Background: Transsphenoidal surgery is standard care in the treatment of hormone-secreting pituitary adenomas. Current clinician-reported surgical outcome measures are one-dimensional, typically focussing primarily on complete or partial resection and secondarily on complication rates. However, outcomes are best reflected by the delicate balance of efficacy and complications at patient level. This study proposes a novel way to classify outcome, integrating efficacy and safety ...

ea0022oc3.3 | Pituitary | ECE2010

Trauma severity, but not hypopituitarism, affects cognitive function after traumatic brain injury: a multi-center study in The Netherlands

Kokshoorn Nieke , Smit Jan , Nieuwlaat Willy-Anne , Biermasz Nienke , Bisschop Peter , Veldman Ronald Groote , Roelfsema Ferdinand , Franken Anton , Wassenaar Moniek , Tiemensma Jitske , Romijn Johannes , Pereira Alberto

Background: Hypopituitarism after traumatic brain injury (TBI) is considered to be a prevalent condition, and may affect quality of life (QoL) and cognitive function. However, the prevalence of hypopituitarism differs considerably among reported studies due to differences in definitions, endocrine assessments of hypopituitarism, and confounding factors, like timing of evaluation and the severity of the trauma.Aim: To evaluate the prevalence of hypopituit...

ea0020p545 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Pre-treatment IGF-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease

Biermasz Nienke R , Wassenaar Moniek J E , van der Klaauw Agatha A , Pereira Alberto M , Smit Johannes W A , Roelfsema Ferdinand , Wolterbeek Ron , Kroon Herman M , Kloppenburg Margreet , Romijn Johannes A

Objective: To identify factors influencing the development of osteoarthritis during long-term control of acromegaly, focusing on disease specific parameters, growth hormone (GH) and insulin-like growth factor I (IGF-I) concentrations and duration of disease, adjusted for the well-known determinants of primary osteoarthritis.Design: Follow-up study.Methods: We studied 67 patients, with adequate biochemical control of acromegaly for ...

ea0056gp202 | Pituitary Clinical | ECE2018

Endoscopic vs microscopic transsphenoidal surgery for Cushing’s disease: a systematic review and meta-analysis

Broersen Leonie H A , Biermasz Nienke R , van Furth Wouter R , de Vries Friso , Verstegen Marco J T , Dekkers Olaf M , Pereira Alberto M

Background: Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, resulting in glucocorticoid excess. First-choice treatment is transsphenoidal pituitary surgery, using either a microscopic or endoscopic technique. Convincing evidence supporting the choice for one of both techniques, either based on treatment results or complication rate, is lacking.Objective: We aimed to compare endoscopic and microscopic...

ea0073oc6.3 | Oral Communications 6: Calcium and Bone | ECE2021

Bone material strength index is altered in patients with Cushing’s syndrome even after long-term remission

Schoeb Manuela , Sintenie Paula J.C. , Haalen Femke van , Nijhoff Michiel , de Vries Friso , Biermasz Nienke , Winter Elizabeth M. , Pereira Alberto M , Appelman-Dijkstra Natasha

BackgroundEndogenous Cushing’s syndrome (CS) is detrimental to bone. The skeletal complications are characterized by decreased bone formation and increased bone resorption, resulting in decreased bone mineral density (BMD) and an increased risk of fractures at time of diagnosis. After remission of the disease, BMD improves towards normal values but fracture rate remains elevated. Therefore, components of bone quality other than BMD, such as bone mat...